-
Anesthesia Drugs Market Poised for Robust Growth, Expected to Reach USD 8.6 Billion by 2032
29 Jan 2025 15:12 GMT
… surgeries. Essential medicines include general anesthetics … chloride)
• Teva Pharmaceuticals – (Etomidate, Vecuronium bromide)
• Mylan – (Lidocaine … , and strong healthcare infrastructure. With the … Drugs Market by Drug
8. Anesthesia Drugs Market …
-
Transdermal Skin Patches Market Expanding Rapidly at 4.79% CAGR to 12.5 Billion USD by 2032 | Medtronic, Purdue Pharma
29 Jan 2025 07:28 GMT
… Pharma
Echo Therapeutics
Mylan
Zynerba Pharmaceuticals … Pharma
Nemaura Medical
HoffmannLa Roche
AdvanSource Biomaterials
Teva Pharmaceutical … healthcare is shaped by emerging technologies such as AI, robotics, and biotechnology …
Drug …
-
Pharmac Reconsiders Oestradiol Patch Options Following Community Feedback
29 Jan 2025 05:10 GMT
… 53 pm
Press Release: PHARMAC
Pharmac is reviewing and reconsidering … Pharmac is working with the suppliers of
Estradot and Estradiol TDP Mylan …
personal situations,” says Pharmac’s Senior Therapeutic
Group … to be available as Pharmac works
through this
process …
-
Pharmac reconsiders decision on HRT oestrogen patches
29 Jan 2025 04:36 GMT
… agency decided only the Mylan-brand patch would be … many people claiming the Mylan-brand patch was less effective … Estradot and Estradiol TDP Mylan on an updated proposal … their personal situations," Pharmac senior therapeutic group manager Alexandra …
-
Psoriatic Arthritis Pipeline Therapeutics Assessment, FDA Approvals, Drugs And Companies | Delveinsight
29 Jan 2025 04:36 GMT
… January 2025:- Janssen Pharmaceuticals:- The purpose of … Therapeutics GmbH, Jiangsu HengRui Medicine Co., Ltd., Nimbus Lakshmi … Arthritis clinical trials, emerging drugs, and market opportunities @ … on patients and the healthcare industry @ Psoriatic Arthritis …
-
Human medicines European public assessment report (EPAR): Ambrisentan Viatris (previously Ambrisentan Mylan), ambrisentan, Date of authorisation: 20/06/2019, Revision: 6, Status: Authorised
27 Jan 2025 22:17 GMT
… bioequivalent’ to the reference medicine. Two medicines are bioequivalent when they … to be followed by healthcare professionals and patients for … code
C02KX02
Pharmacotherapeutic group Antihypertensives
Therapeutic indication
Ambrisentan Mylan is indicated …
-
Human medicines European public assessment report (EPAR): Cinacalcet Viatris (previously Cinacalcet Mylan), cinacalcet, Date of authorisation: 19/11/2015, Revision: 17, Status: Authorised
27 Jan 2025 22:16 GMT
Cinacalcet Viatris is available as tablets, to be taken with food or shortly after a meal.
In patients with secondary hyperparathyroidism, the medicine is taken once a day and the dose is adjusted according to the patient’s PTH and calcium levels.
In …
-
Human medicines European public assessment report (EPAR): Zonisamide Viatris (previously Zonisamide Mylan), zonisamide, Date of authorisation: 31/03/2016, Revision: 11, Status: Authorised
27 Jan 2025 22:16 GMT
The active substance in Zonisamide Viatris, zonisamide, is an anti‑epileptic. Epileptic fits are caused by abnormal electrical activity in the brain.
Zonisamide is thought to work by blocking specific pores on the surface of nerve cells called sodium …
-
Digoxin Effectively Reduces Circulating Tumor Cell Clusters in Metastatic Breast Cancer, Study Finds
30 Jan 2025 23:28 GMT
Treatment with digoxin (Digitek; Mylan Pharmaceuticals Inc) led to partial … from ETH Zurich in Nature Medicine. The agent had encouraging … would lead to development of drugs to target these clusters, … of over 2400 FDA approved drugs, researchers found that Na+…
-
Opioid Market to rise at a 3.4% CAGR from 2024 to 2034 to reach a Valuation of US$ 63,472.6 million | Fact.MR
30 Jan 2025 17:15 GMT
… Plc; Merck KGaA; Teva Pharmaceuticals; Mylan N.V.
Competitive Landscape … Healthcare Limited has been involved in manufacturing and supplying opioid medications … By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Drug Store, Clinics) across …
About
© 1995-2025